Escape mechanisms in tumor immunity: An update

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 21, Issue 4, 2002, Pages 277-330

  Müller, Ludmila ^a   Kiessling, Rolf ^b   Rees, Robert C ^c   Pawelec, Graham ^a,d  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Escape; Immunosurveillance; T cell mediated immunity; Tumor antigen; Tumor rejection

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; HLA ANTIGEN CLASS 1; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL ADHESION; CELLULAR IMMUNITY; DENDRITIC CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TRANSGENIC MOUSE; TUMOR CELL CULTURE; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR REJECTION;

MUS MUSCULUS;

EID: 0036913388     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/jenvironpatholtoxicoloncol.v21.i4.10     Document Type: Review

References (508)

1. Aarli, A. et al: Suppressive effect on lymphoproliferation in vitro by soluble Annexin II released from isolated placental membranes. Am. J. Reprod. Immunol., 38: 313-319 (1997).
2. Agrawal, B. et al.: Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nature. Med., 4: 43-49 (1998a).
3. Agrawal, B. et al.: Expression of MUC1 mucin on activated human T cells. Implications for a role of MUC1 in normal immune regulation. Cancer. Res., 58: 4079-4081 (1998b).
4. Agrawal, B., Gendler, S.J. and Longenecker, B.M.: The biological role of mucins in cellular interactions and immune regulation. Prospects for cancer immunotherapy. Mol. Med. Today, 4: 397-403 (1998c).
5. Agrawal, S. et al.: CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. J. Clin. Invest., 102: 1715-1723 (1998).
6. Alderson, M.R. et al.: Fas transduces activation signals in normal human T-lymphocytes. J. Exp. Med., 178: 2231-2235 (1993).
7. Alexander, J.P. et al.: T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin-2 and express interleukin-2 receptors. Cancer. Res., 53: 1380-1387 (1993).
8. Alexander, R.B. et al.: Helper T cells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes. J. Immunother., 17: 39-46 (1995).
9. Alileche, A. et al.: Human melanoma cell line M14 secretes a functional interleukin-2. Oncogene, 8: 1791-1796 (1993).
10. Alleava, D.G., Burger, C.J. and Elgert, K.D.: Interferongamma reduces tumor-induced macrophage-mediated suppression. Role of prostaglandin-E2 and tumor necrosis factor-alpha. Immunopharmacology, 25: 215-227 (1993).
11. Alleva, D.G., Burger, C.J. and Elgert, K.D.: Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E(2). J. Immunol., 153:1674-1686 (1994).
12. Alleva, D.G., Walker, T.M. and Elgert, K.D.: Induction of macrophage suppressor activity by fibrosarcoma-derived transforming growth factor-beta 1. Contrasting effects on resting and activated macrophages. J. Leukocyte. Biol., 57: 919-925 (1995).
13. Altomonte, M. et al.: Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer. Res., 53: 3343-3348 (1993).
14. Ameglio, F. et al.: Serum interleukin-10 levels in patients affected with multiple myeloma: Correlation with the monoclonal component and disease progression. Int. J. Oncol., 6: 1189-1192 (1995).
15. Amiot, L. et al.: Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br. J. Haematol., 100: 655-663 (1998).
16. Anderson, P. et al.: CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex. Nature, 341: 159-162 (1989).
17. Andersson, P. et al.: Tc-gamma receptor type III (CD16) is included in the NK receptor complex expressed by human natural killer cells. Proc. Natl. Acad. Sci. USA, 87:2274-2278 (1990).
18. Anichini, A., Mortarini, R. and Parmiani, G.: Beta(1)-integrins on melanoma clones regulate the interaction with autologous cytolytic T-cell clones. J. Immunother., 12: 183-186 (1992).
19. Anichini, A. et al.: T-cell-receptor engagement and tumor ICAM-1 up-regulation are required to bypass low susceptibility of melanoma cells to autologous CTL-mediated lysis. Int. J. Cancer., 53: 994-1001 (1993).
20. Anichini, A. et al.: An expanded peripheral T-cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J. Exp. Med., 190: 651-667 (1999).
21. Antonia, S.J. et al.: B7-1 expression by a nonantigen presenting cell-derived tumor. Cancer. Res., 55: 2253-2256 (1995).
22. Antoniou, A. et al.: T-cell tolerance and activation to a transgene-encoded tumor antigen. Eur. J. Immunol., 26: 1094-1102 (1996).
23. Aoe, T., Okamoto, Y. and Saito, T.: Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J. Exp. Med., 181: 1881-1886 (1995).
24. Ardouin, L. et al.: Crippling of CD3-zeta ITAMs does not impair T cell receptor signaling. Immunity, 10: 409-420 (1999).
25. Aruga, A. et al.: Type 1 versus type 2 cytokine release by V beta T-cell subpopulations determines in vivo antitumor reactivity; IL-10 mediates a suppressive role. J. Immunol., 159: 664-673 (1997).
26. Asselin Paturel, C. et al.: Quantitative analysis of Th1, Th2 and TGF-beta 1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int. J. Cancer, 77: 7-12 (1998).
27. Awwad, M. and North, R.J.: Cyclophosphamide-induced immunologically mediated regression of a cyclo-phosphamide-resistant murine tumor. A consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer. Res., 49: 1649-1654 (1989).
28. Awwad, M. and North, R.J.: Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors. Cancer. Res., 50: 2228-2233 (1990).
29. Baeuerle, P.A.: The inducible transcription activator NF-kappa B. Regulation by distinct protein subunits. Biochim. Biophys. Acta., 1072: 63-80 (1991).
30. Banat, G.A. et al.: Tumour-induced suppression of immune response and its correction. Cancer. Immunol. Immunother., 49: 573-586 (2001).
31. Barbera Guillem, E. et al.: B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer. Immunol. Immunother., 48: 541-549 (2000).
32. Barth, R.J. et al.: The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival. Cancer, 78: 1168-1178 (1996).
33. Barzegar, C. et al.: IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. Oncogene, 16: 2503-2512 (1998).
34. Baskar, S. et al.: Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA, 90: 5687-5690 (1993).
35. Beatty, G.L. and Paterson, Y.: IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J. Immunol., 165: 5502-5508 (2000).
36. Beatty, G.L. and Paterson, Y.: IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4(+) T cells requires tumor responsiveness to IFN-gamma. J. Immunol., 166:2276-2282 (2001).
37. Becker, J.C. et al.: Lesion-specific activation of cloned human tumor-infiltrating lymphocytes by autologous tumor cells. Induction of proliferation and cytokine production. J. Invest. Dermatol., 101: 15-21 (1993a).
38. Becker, J.C. et al.: Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T-cell tumor interaction. J. Immunol., 151: 7224-7232 (1993b).
39. + melanoma. Int. Immunol., 5: 1501-1508 (1993c).
40. Becker, J.C., Czerny, C. and Brocker, E.B.: Maintenance of clonal energy by endogenously produced IL-10. Int. Immunol., 6: 1605-1612 (1994).
41. Becker, J.C. et al.: Differential expression of CD28 and CD94/NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node. Eur. J. Immunol., 30: 3699-3706 (2000).
42. Bell, D. et al.: In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med., 190: 1417-1425 (1999).
43. Bellone, G. et al.: Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Amer. J. Pathol., 155: 537-547 (1999).
44. Benitez, R. et al.: Mutations of the beta(2)-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue. Antigen., 52: 520-529 (1998).
45. Benjamin, D., Park, C.D. and Sharma, V.: Human B cell interleukin 10. Leuk. Lymphoma, 12:205 (1994).
46. Bennett, M.W. et al.: The Fas counterattack in vivo. Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol., 160: 5669-5675 (1998).
47. Berghella, A.M. et al.: IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer. Cancer. Biother. Radiopharm., 12: 265-272 (1997).
48. Beverly, B. et al.: Reversal of in vitro T-cell clonal anergy by IL-2 stimulation. Int. Immunol., 4: 661-671 (1992).
49. Black, M.M. et al.: Skin window reactivity to autologous breast cancer. An index of prognostically significant cell-mediated immunity. Cancer, 62: 72-83 (1988).
50. Blay, J., White, T.D. and Hoskin, D.W.: The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer. Res., 57: 2602-2605 (1997).
51. Boussiotis, V.A. et al.: Prevention of T cell anergy by signaling through the gamma(c) chain of the IL-2 receptor. Science, 266: 1039-1042 (1994).
52. Boussiotis, V. et al.: No evidence for MUC 1-induced apoptosis. Nature. Med., 4: 1093 (1998).
53. Bowen, F., Haluskey, J. and Quill, H.: Altered CD40 ligand induction in tolerant T lymphocytes. Eur. J. Immunol., 25: 2830-2834 (1995).
54. Boyano, D. et al.: IL-2 treatment of B16F10 melanoma cells stimulates metastatic colonization in the liver. Anticancer. Res., 17: 1135-1141 (1997).
55. Brady, M.S. et al.: Cytokine production by CD4+T-cells responding to antigen presentation by melanoma cells. Melanoma. Res., 9: 173-180 (1999).
56. Branch, P. et al.: Immune surveillance in colorectal carcinoma. Nat. Genet., 9: 231-232 (1995).
57. Buggins, A.G.S. et al.: Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. Br. J. Haematol., 100: 784-792 (1998).
58. Burnet, F.M. (1970): Immunological Surveillance. Pergamon Press, Oxford.
59. Buzyn, A. et al.: Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells. A mechanism of tumor immune escape in leukemia patients. Blood, 94: 3135-3140 (1999).
60. Bystryn, J.C. et al.: Relationship between immune response to melanoma vaccine immunization and clinical outcome in Stage II malignant melanoma. Cancer, 69: 1157-1164 (1992).
61. Cabrera, T. et al.: High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum. Immunol., 50: 127-134 (1996).
62. Cantwell, M. et al.: Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nature. Med., 3: 984-989 (1997).
63. Capelli, E. et al.: Interleukin-2 induces the growth of human glioblastoma cells in culture. Anticancer. Res., 19: 3147-3151 (1999).
64. Carbone, E. et al.: Recognition of autologous dendritic cells by human NK cells. Eur. J. Immunol., 29: 4022-4029 (1999).
65. Cardi, G. et al.: T-cell receptor xi-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma. Cancer. Res., 57: 3517-3519 (1997).
66. Cardoso, A.A. et al.: Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood, 88: 41-48 (1996).
67. Chan, A.K. et al.: Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation. Int. J. Cancer, 82: 721-726 (1999).
68. Chappell, D.B. and Restifo, N.P.: T cell-tumor cell. A fatal interaction? Cancer. Immunol. Immunother., 47: 65-71 (1998).
69. Chau, G.Y. et al.: Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann. Surg., 231: 552-558 (2000).
70. Chaux, P. et al.: Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab. Invest., 74: 975-983 (1996).
71. Chaux, P. et al.: Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer, 72: 619-624 (1997).
72. Chen, H.L. et al.: A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat. Genet., 13: 210-213 (1996).
73. Chen, L.P. et al.: Costimulation of antitumor immunity by the B7 counterreceptor for the lymphocyte-T molecules CD28 and CTLA-4. Cell, 71: 1093-1102 (1992).
74. Chen, X. et al.: Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Brit. J. Haematol., 111: 817-825 (2000).
75. Choi, S.H. et al.: Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients. Cancer. Immunol. Immunother., 45: 299-305 (1998).
76. Ciacci, C. et al.: Functional interleukin-2 receptors on intestinal epithelial cells. J. Clin. Invest., 92: 527-532 (1993).
77. Ciotti, P. et al.: Intercellular adhesion molecule-1 (ICAM-1) and granulocyte-macrophage colony stimulating factor (GM-CSF) co-expression in cutaneous malignant melanoma lesions. Melanoma. Res., 9: 253-260 (1999).
78. Colombo, M.P. et al.: Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer. Res., 56: 2531-2534 (1996).
79. Contreras, T.N. et al.: Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes. J. Immunother., 23: 67-74 (2000).
80. Cormier, J.N. et al.: Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions. Implications for immunotherapy. J. Immunother., 21: 27-31 (1998).
81. Correa, M.R. et al.: Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J. Immunol., 158: 5292-5296 (1997).
82. Cortes, J.E. et al.: Serum levels of interleukin-10 in patients with diffuse large cell lymphoma. Lack of correlation with prognosis. Blood, 85: 2516-2520 (1995).
83. Cortesina, G. et al.: Interleukin-2 receptors on squamous cell carcinomas of the head and neck. Characterization and functional role. Acta. Oto-Laryngol., 112: 370-375 (1992).
84. Coventry, B.J. et al.: Lack of IL-2 cytokine expression despite IL-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma. Selective expression of early activation markers. J. Immunol., 156: 3486-3492 (1996).
85. Cromme, F.V. et al.: Loss of transporter protein, encoded by the Tap-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med., 179:335-340 (1994).
86. Dam Le, R.N., Advani, S.H. and Gangal, S.G.: Analysis of regulation of T-cell responses by soluble Inhibitory, factors from the sera of patients with Hodgkin's disease. Int. J. Cancer, 50: 192-196 (1992).
87. Dancescu, M. et al.: Interleukin-4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J. Exp. Med., 176: 1319-1326 (1992).
88. Deakin, A.M. et al.: A lack of evidence for down-modulation of CD3 zeta expression in colorectal carcinoma and pregnancy using multiple detection. Clin. Exp. Immunol., 118: 197-204 (1999).
89. Debinski, W. et al.: A wide range of human cancers express interleukin-4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and pseudomonas exotoxin. J. Biol. Chem., 268: 14065-14070 (1993).
90. Denfeld, R.W. et al.: In situ expression of B7 and CD28 receptor families in human malignant melanoma. Relevance for T-cell-mediated anti-tumor immunity. Int. J. Cancer, 62: 259-265 (1995).
91. Dermime, S. et al.: Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant, 19: 989-999 (1997).
92. Desbarats, J. et al.: Dichotomy between naïve and memory CD4(+) T-cell responses to Fas engagement. Proc. Nat. Acad. Sci. USA, 96: 8104-8109 (1999).
93. Desilva, D.R., Urdahl, K.B. and Jenkins, M.K.: Clonal anergy is induced in vitro by T-cell receptor occupancy in the absence of proliferation. J. Immunol., 147:3261-3267 (1991).
94. DeVita, F. et al.: Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer, 86: 1936-1943 (1999).
95. DeVita, F. et al.: Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest, 117: 365-373 (2000).
96. Devries, T.J. et al.: Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer. Res., 57: 3223-3229 (1997).
97. Dianzani, U. et al.: Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies. Correlation with diagnosis and disease status. Blood, 72: 1064-1081 (1988).
98. Diazgallo, C. et al.: An anergic, islet-infiltrating T-cell clone that suppresses murine diabetes secretes a factor that blocks interleukin-2/interleukin-4-dependent proliferation. Proc. Nad. Acad. Sci. USA, 89: 8656-8660 (1992).
99. Diehl, L. et al.: CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature. Med., 5: 774-779 (1999).
100. Djerbi, M. et al.: The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med., 190: 1025-1031 (1999).
101. Donin, N. et al.: Role of immune response as determinant of tumor progression in function of host age in the B16 melanoma. Mech. Aging. Dev., 80: 121-137 (1995).
102. Doran, T. et al.: Oncogene and cytokine expression of human colorectal tumors responding to immunotherapy. J. Immunother., 20: 372-376 (1997).
103. Dowlati, A., Levitan, N. and Remick, S.C.: Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer. J. Lab. Clin. Med., 134: 405-409 (1999).
104. Dudley, M.E. and Roopenian, D.C.: Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J. Exp. Med., 184: 441-447 (1996).
105. Dukers, D.F. et al.: All infiltrating T-lymphocytes in Hodgkin's disease express immunohistochemically detectable T-cell receptor zeta-chains in situ. Histopathology, 36: 544-550 (2000).
106. Dummer, W. et al.: Interleukin-10 production in malignant melanoma. Preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int. J. Cancer, 66: 607-610 (1996).
107. Dunbar, P.R. et al.: A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J. Immunol., 165: 6644-6652 (2000).
108. Dussault, I. and Miller, S.C.: Effectiveness of immunotherapy in aged leukemic mice. Gerontology, 41: 195-204 (1995).
109. Enk, A.H. et al.: Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer, 73: 309-316 (1997).
110. Essery, G., Feldmann, M. and Lamb, J.R.: Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes. Immunology, 64: 413-417 (1988).
111. Farace, F. et al.: The decreased expression of CD3 xi chains in cancer patients is not reversed by IL-2 administration. Int. J. Cancer, 59: 752-755 (1994).
112. Favre Felix, N. et al.: Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. Int. J. Cancer, 86: 827-834 (2000).
113. Fayad, L. et al.: Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia. Correlation with phenotypic characteristics and outcome. Blood, 97: 256-263 (2001).
114. Fijieda, S. et al.: Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma. Cancer, 85: 1439-1445 (1999).
115. Finke, J.H. et al.: Loss of T-cell receptor zeta-chain and p56(lck) in T cells infiltrating human renal cell carcinoma. Cancer. Res., 53: 5613-5616 (1993).
116. Fishman, D. et al.: The role of MHC class I glycoproteins in the regulation of induction of cell death in immunocytes by malignant melanoma cells. Proc. Nat. Acad. Sci. USA, 98: 1740-1744 (2001).
117. Flood, P.M. et al.: Loss of resistance to a highly immunogenic tumor with age corresponds to the decline of CD8 T cell activity. J. Immunother., 21: 307-316 (1998).
118. Fonsatti, E. et al.: In vitro analysis of the melanoma endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells. Cancer. Immunol. Immunother., 48: 132-138 (1999).
119. Fortis, C. et al.: Increased interleukin-10 serum levels in patients with solid tumours. Cancer. Lett., 104: 1-5 (1996).
120. Franco, J.L. et al.: Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice. Cancer. Res., 55: 3840-3846 (1995).
121. Freeman, M.R. et al.: Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor. A potential role for T cells in angiogenesis. Cancer. Res., 55: 4140-4145 (1995).
122. Fujieda, S. et al.: Expression of Fas (CD95) ligand is correlated with IL-10 and granulocyte colony-stimulating factor expression in oral and oropharyngeal squamous cell carcinoma. Cancer. Lett., 161: 73-81 (2000).
123. Gabrilovich, D.I. et al.: Dendritic cells in antitumor immune responses. 2. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell. Immunol., 170: 111-119 (1996a).
124. Gabrilovich, D.I. et al.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature. Med., 2: 1096-1103 (1996b).
125. Ganss, R. and Hanahan, D.: Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer. Res., 58: 4673-4681 (1998).
126. Garcia Lora, A. et al.: Immunoselection by T lymphocytes generates repeated mhc class I-deficient metastatic tumor variants. Int. J. Cancer, 91: 109-119 (2001).
127. Garcia Vazquez, M.D. et al.: Interleukin-2 enhances the growth of human melanoma cells derived from primary but not from metastatic tumours. Eur. Cytokine. Netw., 11: 654-661 (2000).
128. Garrido, F. et al.: Natural history of HLA expression during tumour development. Immunol. Today, 14: 491-499 (1993).
129. Gastl, G.A. et al.: Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int. J. Cancer, 55: 96-101 (1993).
130. Gastman, B.R. et al.: Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer. Res., 59: 1422-1427 (1999a).
131. Gastman, B.R. et al.: Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer. Res., 59: 5356-5364 (1999b).
132. Gati, A. et al.: Tumor cells regulate the lytic activity of tumor-specific cytotoxic T lymphocytes by modulating the inhibitory natural killer receptor function. Cancer. Res., 61: 3240-3244 (2001).
133. Gaya, S.B.M. et al.: Malignant disease in patients with long-term renal transplants. Transplantation, 59: 1705-1709 (1995).
134. Geertsen, R.C. et al.: Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions. J. Invest. Dermatol., 111: 497-502 (1998).
135. Gelber, C. et al.: T-cell subset analysis of Lewis lung carcinoma tumor rejection. Heterogeneity of effectors and evidence for negative regulatory lymphocytes correlating with metastasis. Cancer. Res., 52: 6507-6515 (1992).
136. Ghosh, P. et al.: Alterations in NF kappa B/Rel family proteins in splenic T cells from tumor-bearing mice and reversal following therapy. Cancer. Res., 54: 2969-2972 (1994).
137. Ghosh, P. et al.: Loss of Th1 DNA-binding pattern and alterations in signal transduction molecules in T cells of renal cell carcinoma patients. 9th Int. Congress Immunol. Abstract Book. Abstract 3936 (1995).
138. Gimmi, C.D. et al.: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA, 90: 6586-6590 (1993).
139. Gimmi, C.D. et al.: Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature. Med., 2: 1367-1370 (1996).
140. Giorda, R. and Trucco, M.: Mouse NKR-P. A family of genes selectively coexpressed in adherent lymphokine-activated killer cells. J. Immunol., 147: 1701-1708 (1991).
141. Giovarelli, M. et al.: Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J. Immunol., 155: 3112-3123 (1995).
142. Girolomoni, G. and Ricciardicastagnoli, P.: Dendritic cells hold promise for immunotherapy. Immunol. Today, 18: 102-104 (1997).
143. Golumbek, P.T. et al.: Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science, 254: 713-716 (1991).
144. Gratama, J.W. et al.: Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy. Cancer. Immunol. Immunother., 48: 263-269 (1999).
145. Gratas, C. et al.: Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer. Res., 58: 2057-2062 (1998).
146. Grever, M.R. et al.: The effect of oxidative stress on human lymphocyte cytotoxicity. Blood, 56: 284-288 (1980).
147. Grothey, A. et al.: Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer. Correlation with histological expression of ICAM-1 and tumour stage. Br. J. Cancer, 77: 801-807 (1998).
148. Groux, H. et al.: A CD4(+) T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature, 389: 737-742 (1997).
149. Guerra, N. et al.: Effect of tumor growth factor-beta on NK receptor expression by allostimulated CD8(+) T lymphocytes. Eur. Cytokine. Netw., 10: 357-363 (1999).
150. Guindi, M.: Role of activated host T cells in the promotion of MALT lymphoma growth. Semin. Cancer. Biol., 10: 341-344 (2000).
151. Gunji, Y. et al.: High frequency of cancer patients with abnormal assembly of the T-cell receptor-CD3 complex in peripheral blood T lymphocytes. Jpn. J. Cancer. Res., 85: 1189-1192 (1994).
152. Hagenbaugh, A. et al.: Altered immune responses in interleukin 10 transgenic mice. J. Exp. Med., 185: 2101-2110 (1997).
153. Hahne, M. et al.: Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science, 274: 1363-1366 (1996).
154. Hakansson, A. et al.: On down-regulation of the immune response to metastatic malignant melanoma. Cancer. Immunol. Immunother., 48: 253-262 (1999).
155. Halder, T.M. et al.: Defensins are dominant HLA-DR-associated self-peptides from CD34(-) peripheral blood mononuclear cells of different tumor patients (Plasmacytoma, chronic myeloid leukemia). Blood, 95: 2890-2896 (2000).
156. Hammond, W.G. et al.: Tumor progression by lung cancers growing in hosts of different immunocompetence. Canc. J., 8: 130-138 (1995).
157. Han, D.S. et al.: IL2 triggers a tumor progression process in a melanoma cell line MELP, derived from a patient whose metastasis increased in size during IL2/INF alpha biotherapy. Oncogene, 12: 1015-1023 (1996).
158. Handelfernandez, M.E. et al.: Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice. J. Immunol., 158: 280-286 (1997).
159. Hansen, E.R. et al.: In cutaneous T-cell lymphoma, class II MHC molecules on CD1(+) antigen-presenting cells are upregulated in involved compared with uninvolved epidermis. Br. J. Dermatol., 131: 780-788 (1994).
160. Harada, H. et al.: Anti-oncogenic and oncogenic potentials of interferon regulatory factor-1 and factor-2. Science, 259: 971-974 (1993).
161. Hatakeyama, M. et al.: Interaction of the IL-2 receptor with the src-family kinase-P56lck. Identification of novel intermolecular association. Science, 252: 1523-1528 (1991).
162. Healy, C.G. et al.: Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry, 32: 109-119 (1998).
163. Heinzel, S. et al.: The self peptide Annexin II (208-223) presented by dendritic cells sensitizes autologous CD4+T lymphocytes to recognize melanoma cells. Cancer. Immunol. Immunother., 49: 671-678 (2001).
164. Hellstrand, K. et al.: Histaminergic receptors on NK cells. J. Immunol., 153: 4940 (1994).
165. Hersey, P. et al.: Expression of the co-stimulatory molecule B7 on melanoma cells. Int. J. Cancer, 58: 527-532 (1994).
166. Heys, S.D. et al.: Expression of the intermediate affinity interleukin 2 receptor by a human solid tumour cell line. Evidence for functional activity. Int. J. Oncol., 5: 931-935 (1994).
167. Hicklin, D.J. et al.: Beta 2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J. Clin. Invest., 101: 2720-2729 (1998).
168. Hishii, M. et al.: Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery, 37: 1160-1166 (1995).
169. Hofbauer, G.F.L. et al.: Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma. Frequency and distribution. Melanoma. Res., 8: 337-343 (1998).
170. lck. Proc. Natl. Acad. Sci. USA, 88: 1996-2000 (1991).
171. Horiuchi, S. and Wilmoth, J.R.: Age patterns of the life table aging rate for major causes of death in Japan, 1951-1990. J. Gerontol. Ser. A - Biol. Sci. Med., 52: B67-B77 (1997).
172. Hoskin, D.W., Reynolds, T. and Blay, J.: Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumors. Int. J. Cancer, 59: 854-855 (1994).
173. Hsu, S.C., Glaves, D. and Sood, A.K.: Interleukin-2 secretion by KHT sarcoma cells leads to lass of their vaccine potential. Cancer. Immunol. Immunother., 44: 117-124 (1997).
174. Huang, M. et al.: Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer. Res., 55: 3847-3853 (1995).
175. Huang, M. et al.: Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J. Immunol., 157: 5512-5520 (1996).
176. Huang, S.Y., Ullrich, S.E. and Bar Eli, M.: Regulation of tumor growth and metastasis by interleukin-10. The melanoma experience. J. Interferon. Cytokine. Res., 19: 697-703 (1999).
177. Hudson, J.D. et al.: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med., 190: 1375-1382 (1999).
178. Hünig, T: T-cell function and specificity in athymic mice. Immunol. Today, 4: 84-87 (1983).
179. Hui, K., Grosveld, F. and Festenstein, H.: Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature, 311: 750 (1984).
180. Hurks, H.M.H. et al.: High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines. Int. J. Cancer, 85: 697-702 (2000).
181. Hutloff, A. et al.: ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature, 397: 263-266 (1999).
182. Ikeda, H. et al.: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity, 6: 199-208 (1997a).
183. Ikeda, H. et al.: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity, 6:199-208 (1997b).
184. Imaida, K. et al.: Clinicopathological analysis on cancers of autopsy cases in a geriatric hospital. Pathol. Int., 47: 293-300 (1997).
185. Inaba, M. et al.: Primed T cells are more resistant to Fas-mediated activation-induced cell death than naïve T cells. J. Immunol., 163: 1315-1320 (1999).
186. Izumi, M. et al.: Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in non-small cell lung carcinoma. Cancer, 92: 446-451 (2001).
187. Jager, E. et al.: Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8(+) cytotoxic T-cell responses. Evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer, 66: 470-476 (1996).
188. Jager, E. et al.: Immunoselection in vivo. Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer, 71: 142-147 (1997).
189. Jaiswal, M. et al.: Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer. Res., 60: 184-190 (2000).
190. Jarnicki, A.G. et al.: Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma. Cancer. Lett., 103: 1-9 (1996).
191. Jenkins, M.K.: Tne role of cell division in the induction of clonal anergy. Immunol. Today, 13: 69-73 (1992).
192. Jodo, S. et al.: Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin. Exp. Immunol., 112: 166-171 (1998).
193. Johnsen, A. et al.: Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer. Res., 58: 3660-3667 (1998).
194. Johnsen, A.K. et al.: Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J. Immunol., 163: 4224-4231 (1999).
195. Jonas, S. et al.: De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer, 80: 1141-1150 (1997).
196. Kageshita, T. et al.: Down-regulation of HLA class I antigen-processing molecules in malignant melanoma. Association with disease progression. Amer. J. Pathol., 154: 745-754 (1999).
197. Kaklamanis, L. et al.: Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am. J. Pathol., 145: 505-509 (1994).
198. Kang, S.M. et al.: NF-kappa-B subunit regulation in nontransformed CD4+ lymphocytes-T. Science, 256: 1452-1456 (1992).
199. Kang, S.M. et al.: Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature. Med., 3: 738-743 (1997).
200. Karre, K., Ljunggren, H.-G. and Kiessling, R.: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature, 319: 675-678 (1986).
201. Kemppainen, M., Raiha, I. and Sourander, L.: Influence of age on colorectal cancer's 5-year survival. Gerontology, 41: 145-151 (1995).
202. Kharkevitch, D.D. et al.: Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Int. J. Cancer, 58: 317-323 (1994).
203. Kiertscher, S.M. et al.: Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J. Immunol., 164: 1269-1276 (2000).
204. Kim, J. et al.: IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T-cell immune response. J. Immunol., 155:2240-2247(1995).
205. Kim, J.A. et al.: Modulation of CD4 cell cytokine production by colon cancer-associated mucin. Cancer. Immunol. Immunother., 48: 525-532 (1999).
206. Kirkin, A.F., Straten, P.T. and Zeuthen, J.: Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T-cell clones that recognize differentiation or progression antigens. Cancer. Immunol. Immunother., 42: 203-212 (1996).
207. Kirnbauer, R. et al.: Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells. Evidence for a regulatory role of IL-6, IL-7, TNFbeta, and UVB Light. J. Invest. Dermatol., 98: 320-326 (1992).
208. Kjaergaard, J. and Shu, S.Y.: Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. J. Immunol., 163: 751-759 (1999).
209. Koeppen, H. et al.: Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes. Eur. J. Immunol., 23: 2770-2776 (1993).
210. Kolb, H.J. et al.: Malignant neoplasms in long-term survivors of bone marrow transplantation. Ann. Intern. Med., 131: 738+ (1999).
211. Kolenko, V. et al.: Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling. Role of soluble products from human renal cell carcinomas. J. Immunol., 159: 3057-3067 (1997).
212. Kono, K. et al.: Decreased expression of signal-transducing zeta chain on peripheral T cells and NK cells in patients with cervical cancer. Clinical Cancer Research, 2: 1825 (1996a).
213. Kono, K. et al.: Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T-cell- and natural killer cell-mediated cytotoxicity. Eur. J. Immunol., 26: 1308-1313 (1996b).
214. Kono, K. et al.: Differences in the recognition of tumor-specific CD8(+) T cells derived from solid tumor, metastatic lymph nodes and ascites in patients with gastric cancer. Int. J. Cancer, 71: 978-981 (1997a).
215. Kono, K. et al.: Mechanisms of escape from CD8(+) T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas. Related and unrelated to decreased MHC class 1 expression. Int. J. Cancer, 70: 112-119 (1997b).
216. Kontani, K. et al.: Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Brit. J. Cancer, 84: 1258-1264 (2001).
217. Koopman, L.A. et al.: Human leukocyte antigen class I gene mutations in cervical cancer. J. Nat. Cancer. Inst., 91: 1669-1677 (1999).
218. Koopman, L.A. et al.: Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J. Exp. Med., 191: 961-975 (2000).
219. Korkolopoulou, P. et al.: Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br. J. Cancer, 73: 148-153 (1996).
220. Koulis, A. et al.: Characterization of tumor-infiltrating T lymphocytes in B-cell lymphomas of mucosa-associated lymphoid tissue. Am. J. Pathol., 151: 1353-1360 (1997).
221. Koyama, S. et al.: Expression of costimulatory molecules, B7-1 and B7-2 on human gastric carcinoma. J. Cancer. Res. Clin. Oncol., 124: 383-388 (1998).
222. Koyama, S., Koike, N. and Adachi, S.: Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J. Cancer. Res. Clin. Oncol., 127: 20-26 (2001).
223. Krasagakis, K. et al.: Elevated plasma levels of transforming growth factor (TGF)-beta 1 and TGF-beta 2 in patients with disseminated malignant melanoma. Br. J. Cancer, 77: 1492-1494 (1998).
224. Krugerkrasagakes, S. et al.: Expression of interleukin 10 in human melanoma. Br. J. Cancer, 70: 1182-1185 (1994).
225. Kudoh, S. et al.: T lymphocytes infiltrating renal cell carcinoma have a reduced expression of transferrin receptor. Int. J. Cancer, 58: 369-375 (1994).
226. Kume, T. et al.: Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepithelioma-like cancer of the stomach. Int. J. Cancer, 84: 339-343 (1999).
227. Kunz, M. et al.: Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness. Amer. J. Pathol., 155: 753-763 (1999).
228. Kurt, R.A. et al.: T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities. J. Immunol., 154: 3969-3974 (1995).
229. Kurt, R.A. et al.: Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules. Int. J. Cancer, 78: 16-20 (1998).
230. Lai, P. et al.: Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clinical Cancer Research, 2: 161-173 (1996).
231. Lanier, L.L. and Phillips, J.H.: Inhibitory MHC class I receptors on NK cells and T cells. Immunol. Today, 17: 86-91 (1996).
232. Lanier, L.L., Yu, G. and Phillips, J.H.: Co-association of CD3xi with a receptor (CD16) for IgG Fc on human natural killer cells. Nature, 342: 803-805 (1989).
233. Lauritzsen, G.F. et al.: Clonal deletion of thymocytes as a tumor escape mechanism. Int. J. Cancer, 78: 216-222 (1998).
234. Leach, D.R., Krummel, M.F. and Allison, J.P.: Enhancement of antitumor immunity by CTLA-4 blockade. Science, 271: 1734-1736 (1996).
235. Lee, K.H. et al.: Functional dissociation between local and systemic immune response during antimelanoma peptide vaccination. J. Immunol., 161: 4183-4194 (1998).
236. Lee, P.P. et al.: T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood, 90: 1611-1617 (1997).
237. Lee, P.P. et al.: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature. Med., 5: 677-685 (1999).
238. LeGal, F.A. et al.: HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int. Immunol., 11: 1351-1356 (1999).
239. LeGuiner, S. et al.: LFA-3 co-stimulates cytokine secretion by cytotoxic T lymphocytes by providing a TCR-independent activation signal. Eur. J. Immunol., 28: 1322-1331 (1998).
240. Lehmann, F. et al.: Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol., 25: 340-347 (1995).
241. Leong, C.C. et al.: Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma. Int. J. Cancer, 71: 476-482 (1997).
242. Lethe, B. et al.: MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma. Res., 7: S83-S88 (1997).
243. Levey, D.L. and Srivastava, P.K.: T cells from late tumor-bearing mice express normal levels of p56(lck), p59(fyn), ZAP-70, and CD3 zeta despite suppressed cytolytic activity. J. Exp. Med., 182: 1029-1036 (1995).
244. Li, X. et al.: T cells from renal carcinoma patients show an abnormal pattern of kappa B-specific DNA-binding activity. A preliminary analysis. Cancer. Res., 54: 5424-5429 (1994).
245. Lindelof, B. et al.: Incidence of skin cancer in 5356 patients following organ transplantation. Brit. J. Dermatol., 143: 513-519 (2000).
246. Ling, W.J. et al.: Impaired activation of NF Kappa B in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, I Kappa B alpha. Blood, 92: 1334-1341 (1998).
247. Link, A.A. et al.: Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J. Immunol., 164: 436-442 (2000).
248. Liossis, S.N.C. et al.: Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J. Clin. Invest., 101: 1448-1457 (1998).
249. Liou, H.C. and Baltimore, D.: Regulation of the NF kappa B/rel transcriptional and I kappa B inhibitor system. Curr. Opin. Cell. Biol., 5: 477-487 (1993).
250. Liu, L.M. et al.: Induction of T(h)2 cell differentiation in the primary immune response. Dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4(+) T cells to secrete IL-4. Int. Immunol., 10: 1017-1026 (1998).
251. Loercher, A.E. et al.: Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J. Immunol., 163: 6251-6260 (1999).
252. Loftus, D.J. et al.: Peptides derived from self-proteins as partial agonists and antagonists of human CD8(+) T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). Cancer. Res., 58: 2433-2439 (1998).
253. Lombardi, G. et al.: Anergic T cells as suppressor cells in vitro. Science, 264: 1587-1589 (1994).
254. Lowes, M.A. et al.: T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J. Invest. Dermatol., 108: 914-919 (1997).
255. Lutz, C.T. and Kurago, Z.B.: Human leukocyte antigen class I expression on squamous cell carcinoma cells regulates natural killer cell activity. Cancer. Res., 59: 5793-5799 (1999).
256. Maclean, G.D., Reddish, M.A. and Longenecker, B.M.: Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. J. Immunother., 20: 70-78 (1997).
257. Maeda, H. and Shiraishi, A.: TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol., 156: 73-78 (1996).
258. Maeurer, M.J. et al.: Tumor escape from immune recognition. Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest., 98: 1633-1641 (1996).
259. Malefyt, R.D. et al.: Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes. An autoregulatory role of IL-10 produced by monocytes. J. Exp. Med., 174: 1209-1220 (1991).
260. Manson, L.A.: Does antibody-dependent epitope masking permit progressive tumour growth in the face of cell-mediated cytotoxicity? Immunol. Today, 12: 352-355 (1991).
261. Mantovani, A. et al.: The origin and function of tumor-associated macrophages. Immunol. Today, 13: 265-270 (1992).
262. Mantovani, G. et al.: Lack of correlation between defective cell-mediated immunity and levels of secreted or circulating cytokines in a study of 90 cancer patients. Clinical study. Int. J. Oncol., 5: 1211-1217 (1994).
263. Mantovani, G. et al.: Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int. J. Cancer, 71: 724-731 (1997).
264. Marincola, F.M. et al.: Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J. Immunol., 153: 1225-1237 (1994).
265. Martinotti, A. et al.: CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol., 25: 137-146 (1995).
266. Massaia, M. et al.: Correlation between disease activity and T-cell CD3 zeta chain expression in a B-cell lymphoma. Br. J. Haematol., 88: 886-888 (1994).
267. Massaia, M. et al.: Dysregulated Fas and bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood, 85: 3679-3687 (1995).
268. Matsuda, M. et al.: Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med., 180: 2371-2376 (1994).
269. Matsuda, M. et al.: Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes. Correlation with the stage of the disease. Int. J. Cancer, 61: 765-772 (1995).
270. Matsuda, M. et al.: Decreased expression of signal-transducing CD3 zeta chains in T cells from the joints and peripheral blood of rheumatoid arthritis patients. Scand. J. Immunol., 47: 254-262 (1998).
271. Matsui, S. et al.: A model for CD8(+) CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J. Immunol., 163: 184-193 (1999).
272. Maurice, M.M. et al.: Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. J. Immunol., 159: 2973-2978 (1997).
273. Maxwell, E. et al.: In vivo effects of hIL-10 on the growth of various tumors. Proc. Am. Assoc. Cancer Res., 35: 480 (Abstract) (1994).
274. McKallip, R., Li, R.X. and Ladisch, S.: Tumor gangliosides inhibit the tumor-specific immune response. J. Immunol., 163: 3718-3726 (1999).
275. McMillan, D.N. et al.: Interleukin 2 receptor expression and interleukin 2 localisation in human solid tumour cells in situ and in vitro. Evidence for a direct role in the regulation of tumour cell proliferation. Int. J. Cancer, 60: 766-772 (1995).
276. Medema, J.P. et al.: Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med., 190: 1033-1038 (1999).
277. Medot Pirenne, M. et al.: Augmentation of an antitumor CTL response in vivo by inhibition of suppressor macrophage nitric oxide. J. Immunol., 163: 5877-5882 (1999).
278. Mellado, M. et al.: A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T-cell death. Curr. Biol., 11: 691-696 (2001).
279. Mellor, A.L. and Munn, D.H.: Tryptophan catabolism and T-cell tolerance. Immunosuppression by starvation? Immunol. Today, 20: 469-473 (1999).
280. Menetrier Caux, C. et al.: Renal cell carcinoma induces interleukin 10 and prostaglandin E-2 production by monocytes. Brit. J. Cancer, 79: 119-130 (1999).
281. Merl, A. et al. (1996): Expression of cytokine receptors on anergic CD4+ TCR2+ THO cell clones. In: Leukocyte Tyong VI. Kishimoto, T., in press.
282. Miescher, S. et al.: Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors. Effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol., 136: 1899-1904 (1986).
283. Miescher, S. et al.: Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J. Immunol., 138: 4004-4011 (1987).
284. Miller, R.A.: Gerontology as oncology. Research on aging as the key to the understanding of cancer. Cancer, 68: 2496-2501 (1991).
285. Mingari, M.C. et al.: HLA class I-specific inhibitory receptors in human T lymphocytes. Interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8(+) T cells. Proc. Natl. Acad. Sci. USA, 95: 1172-1177 (1998).
286. Mizoguchi, H. et al.: Alterations in signal transduction molecules in lymphocytes-T from tumor-bearing mice. Science, 258: 1795-1798 (1992).
287. Moretta, A. et al. (1996): Receptors for HLA class I molecules in human natural killer cells. Annu Rev Immunol; 14619-648.
288. Moretti, S. et al.: Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int. J. Cancer, 84: 160-168 (1999).
289. Morford, L.A. et al.: T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J. Immunol., 159: 4415-4425 (1997).
290. Morioka, A. et al.: Effects of non-MHC background genes on the induction of CD4+ T-cells that prevent rejection of a highly immunogenic tumor, FBL-3. Int. Immunol., 6: 839-846 (1994).
291. Mouawad, R. et al.: Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy? Melanoma. Res., 9: 181-188 (1999).
292. Mukai, S. et al.: Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer. Res., 59: 5245-5249 (1999).
293. Mukherji, B. et al.: Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J. Exp. Med., 169: 1961-1976 (1989).
294. Mulder, W.M. et al.: T cell receptor zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut, 40: 113 (1997).
295. Muschen, M. et al.: CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology, 99: 69-77 (2000).
296. Nagao, M. et al.: The alteration of Fas receptor and ligand system in hepatocellular carcinomas. How do hepatoma cells escape from the host immune surveillance in vivo? Hepatology, 30: 413-421 (1999).
297. Nagashima, H. et al.: Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis. Int. J. Oncol., 18:1157-1162 (2001).
298. Nakagomi, H. et al.: Decreased expression of the signal-transducing zeta-chains in tumor-infiltrating T-Cells and NK cells of patients with colorectal carcinoma. Cancer. Res., 53: 5610-5612 (1993).
299. Nakagomi, H. et al.: Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int. J. Cancer, 63: 366-371 (1995).
300. Nakajima, C. et al.: A role of interferon-gamma (IFN-gamma) in tumor immunity. T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice. Cancer. Res., 61: 3399-3405 (2001).
301. Nakamoto, Y. et al.: Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med., 188: 341-350 (1998).
302. Nakashima, M., Sonoda, K. and Watanabe, T.: Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nature. Med., 5: 938-942 (1999).
303. Nestle, F.O. et al.: Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am. J. Pathol., 150: 641-651 (1997).
304. Niehans, G.A. et al.: Human lung carcinomas express Fas ligand. Cancer. Res., 57: 1007-1012 (1997).
305. Nieland, J.D. et al.: PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impaired. J. Immunother., 21: 317-322 (1998).
306. Ninomiya, T. et al.: Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J. Hepatol., 31: 323-331 (1999).
307. Nishimura, T. et al.: Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med., 190: 617-627 (1999).
308. Noppen, C. et al.: C-type lectin-like receptors in peptide-specific HLA class I-restricted cytotoxic T lymphocytes. Differential expression and modulation of effector functions in clones sharing identical TCR structure and epitope specificity. Eur. J. Immunol., 28: 1134-1142 (1998).
309. North, R.J. and Awwad, M.: Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology., 71: 90-95 (1990).
310. Nurnberg, W. et al.: Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J. Pathol., 189: 546-551 (1999).
311. Nyhus, J.K. et al.: Direct in vivo transfection of antisense Fas-ligand reduces tumor growth and invasion. Gene. Therapy, 8: 209-214 (2001).
312. O'Connell, J. et al.: Expression of fas (CD95/APO-1) ligand by human breast cancers. Significance for tumor immune privilege. Clin. Diagn. Lab. Immunol., 6: 457-463 (1999).
313. Ohlen, C. et al.: Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8(+) T cells or CTL immunotherapy of tumors expressing the antigen. J. Immunol., 166: 2863-2870 (2001).
314. Olsen, A.C. et al.: A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses. Scand. J. Immunol., 41: 357-364 (1995).
315. O'Neil, B.H. et al.: Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J. Immunol., 151: 1410-1418 (1993).
316. Onizuka, S. et al.: Tumor rejection by in vivo administration of anti-CD25 (Interleukin-2 receptor alpha) monoclonal antibody. Cancer. Res., 59: 3128-3133 (1999).
317. Ono, S., Ohno, H. and Saito, T.: Rapid turnover of the CD3 zeta chain independent of the TCR-CD3 complex in normal T cells. Immunity, 2: 639-644 (1995).
318. Otsuji, M. et al.: Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. USA, 93: 13119-13124 (1996).
319. Owen Schaub, L.B. et al.: Fas and fas-ligand interactions suppress melanoma lung metastasis. J. Exp. Med., 188: 1717-1723 (1998).
320. Paglieroni,T., Caggiano, V. and MacKenzie, M.: Abnormalities in immune regulation precede the development of multiple myeloma. Am. J. Hematol., 40: 51-55 (1992).
321. Pak, A.S. et al.: Treating tumor-bearing mice with low-dose gamma- interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy. Cancer. Res., 55: 885-890 (1995).
322. Palomares, T. et al.: The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma. Cancer. Immunol. Immunother., 40: 292-298 (1995).
323. Pandolfi, F. et al.: Expression of cell adhesion molecules in human melanoma cell lines and their Role in cytotoxicity Mediated by tumor-infiltrating lymphocytes. Cancer, 69: 1165-1173 (1992).
324. Paul, P. et al.: HLA-G expression in melanoma. A way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. USA, 95: 4510-4515 (1998).
325. Paul, S. et al.: Lack of evidence for an immunosuppressive role for MUC1. Cancer. Immunol. Immunother., 48: 22-28 (1999).
326. Pawelec, G.: Tumour escape from the immune response. The last hurdle for successful immunotherapy of cancer? Cancer. Immunol. Immunother., 48: 343-345 (1999).
327. Pawelec, G.P. et al.: IL-4-responsive human helper T cell clones are resistant to growth inhibition by tumor necrosis factor-α. J. Immunol., 143: 902-906 (1989).
328. Pawelec, G. et al.: Requirements for stimulation or anergy induction in alloreactive human T cell clones. Cell. Immunol., 158: 241-252 (1994).
329. Pawelec, G. et al.: Immunosenescence. Aging of the immune system. Immunol. Today, 16: 420-422 (1995a).
330. Pawelec, G. et al.: Interleukin 10 is a human T cell growth factor in vitro. Cytokine, 7: 355-363 (1995b).
331. Pawelec, G. et al.: Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro. Cancer. Immunol. Immunother., 42: 193-199 (1996a).
332. Pawelec, G. et al.: Decreased proliferative capacity and increased susceptibility to activation-induced cell death in late-passage human CD4(+) TCR2(+) cultured T cell clones. Exp. Gerontol., 31: 655-668 (1996b).
333. Pawelec, G. et al.: Interleukin 10 protects activated human T lymphocytes against growth factor withdrawal-induced cell death but only anti-fas antibody can prevent activation-induced cell death. Cytokine, 8: 877-881 (1996c).
334. Pawelec, G. et al.: T cell immunosenescence in vitro and in vivo. Exp. Gerontol., 34: 419-429 (1999a).
335. Pawelec, G. et al.: T cells and aging. Front. Biosci., 4: d216 (www.bioscience.org) (1999b).
336. Pawelec, G., Schlotz, E. and Rehbein, A.: IFN-alpha regulates IL-10 production by CML cells in vitro. Cancer. Immunol. Immunother., 48: 430-434 (1999c).
337. Pekarek, L.A. et al.: Inhibition of tumor growth by elimination of granulocytes. J. Exp. Med., 181: 435-440 (1995).
338. Pellegrini, P. et al.: Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer. Immunol. Immunother., 42: 1-8 (1996).
339. Pende, D. et al.: The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur. J. Immunol., 28: 2384-2394 (1998).
340. Peng, L.M., Shu, S.Y. and Krauss, J.C.: Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells. Cancer. Res., 57: 4849-4854 (1997).
341. Peoples, G.E. et al.: T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor. A potential pathologic role. Proc. Natl. Acad. Sci. USA, 92: 6547-6551 (1995).
342. Pericle, F. et al.: Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. J. Immunol., 159: 2580-2585 (1997).
343. Peshwa, M.V. et al.: Generation of primary peptide-specific CD8(+) cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells. Cell. Transplant, 7: 1-9 (1998).
344. Petersson, M. et al.: Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J. Immunol., 161: 2099-2105 (1998).
345. Philip, T. et al.: Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients. Br. J. Cancer, 68: 1036-1042 (1993).
346. Pisa, P. et al.: Selective expression of interleukin-10, interferon-gamma, and granulocyte macrophage colony-stimulating factor in ovarian cancer biopsies. Proc. Natl. Acad. Sci. USA, 89: 7708-7712 (1992).
347. Pitti, R.M. et al.: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature, 396: 699-703 (1998).
348. Ponzio, N.M. and Thorbecke, G.J.: Requirement for reverse immune surveillance for the growth of germinal center-derived murine lymphomas. Semin. Cancer. Biol., 10: 331-340 (2000).
349. Poppema, S. and van den Berg, A.: Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin. Cancer. Biol., 10: 345-350 (2000).
350. Powrie, F., Menon, S. and Coffman, R.L.: Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur. J. Immunol., 23: 3043-3049 (1993).
351. Prehn, R.T.: Stimulatory effects of immune reactions upon the growths of untransplanted Tumors. Cancer. Res., 54: 908-914 (1994).
352. Prehn, R.T.: On the probability of effective anticancer vaccines. Canc. J., 8: 284-285 (1995).
353. Puri, R.K. et al.: Expression of high-affinity IL-4 receptors on murine tumour infiltrating lymphocytes and their up-regulation by IL-2. Immunology, 70: 492-497 (1990).
354. Qin, Z.H. et al.: Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocytemacrophage colony-stimulating factor gene-modified tumor cells. J. Immunol., 159: 770-776 (1997).
355. Qin, Z.H. et al.: B cells inhibit induction of T-cell-dependent tumor immunity. Nature. Med., 4: 627-630 (1998).
356. Rabinowich, H. et al.: Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int. J. Cancer, 68: 276-284 (1996).
357. Rabinowich, H. et al.: Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest., 101: 2579-2588 (1998).
358. Radoja, S. et al.: Mice bearing late-stage tumors have normal functional systemic T-cell responses in vitro and in vivo. J. Immunol., 164: 2619-2628 (2000).
359. Ragg, S.J. et al.: Failure of carcinogen-altered dendritic cells to initiate T-cell proliferation is associated with reduced IL-1 beta secretion. Cell. Immunol., 178: 17-23 (1997).
360. Rakhmilevich,A.L. and North, R.J.: Elimination of Cd4+ T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2. Cancer. Immunol. Immunother., 38: 107-112 (1994).
361. Rayman, P. et al.: Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling. A mechanism of immune escape. Cancer. J. Sci. Am., 6: S81-S87 (2000).
362. Real, L.M. et al.: Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer. Immunol. Immunother., 49: 621-628 (2001).
363. Reichert, T.E. et al.: Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer. Res., 58: 5344-5347 (1998).
364. Reichert, T.E. et al.: The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines. Brit. J. Cancer, 81: 822-831 (1999).
365. Remarque, E. and Pawelec, G.: T cell immunosenescence and its clinical relevance in man. Rev. Clin. Gerontol., 8: 5-25 (1998).
366. Renner, C. et al.: T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood, 88: 236-241 (1996).
367. Restifo, N.P.: Not so Fas. Re-evaluating the mechanisms of immune privilege and tumor escape. Nature. Med., 6: 493-495 (2000).
368. Restifo, N.P. et al.: A nonimmunogenic sarcoma transduced with the cDNA for interferon-gamma elicits CD8+ T-cells against the wild-type tumor. Correlation with antigen presentation capability. J. Exp. Med., 175: 1423-1431 (1992).
369. Restifo, N.P. et al.: Identification of human cancers deficient in antigen processing. J. Exp. Med., 177: 265-272 (1993).
370. Restifo, N.P. et al.: Loss of functional beta(2)-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Nat. Cancer. Inst., 88: 100-108 (1996).
371. Richter, G. et al.: Interleukin-10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer. Res., 53: 4134-4137 (1993).
372. Riker, A. et al.: Immune selection after antigen-specific immunotherapy of melanoma. Surgery, 126: 112-120 (1999).
373. Rimoldi, D. et al.: Expression of IL-2 receptors in human melanoma cells. Anticancer. Res., 13: 555-564 (1993).
374. Rivoltini, L. et al.:- Human melanoma-reactive CD4(+) and CD8(+) CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J. Immunol., 161: 1220-1230 (1998).
375. Robbins, P.F. et al.: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J. Immunol., 154:5944-5950 (1995).
376. Rodolfo, M. et al.: IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon
377. Rohrer, J.W. and Coggin, J.H.: CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J. Immunol., 155: 5719-5727 (1995).
378. Rohrer, J.W. et al.: Characterization of RFM mouse T lymphocyte anti-oncofetal antigen immunity in apparent tumor-free, long-term survivors of sublethal x-irradiation by limiting dilution T lymphocyte cloning. J. Immunol., 154: 2266-2280 (1995).
379. Rosen, H.R. et al.: Downregulation of lymphocyte mitogenesis by breast cancer-associated p43. Cancer. Lett., 82: 105-111 (1994).
380. Rossi, E. et al.: Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia., 10: 494-497 (1996).
381. Rowse, G.J., Weinberg, J. and Emerman, J.T.: Role of natural killer cells in psychosocial stressor-induced changes in mouse mammary tumor growth. Cancer. Res., 55: 617-622 (1995).
382. Rudy, W. et al.: Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-gamma. Int. Immunol., 9: 853-860 (1997).
383. Ryu, B.K. et al.: Increased expression of cFLIP(L) in colonic adeno carcinoma. J. Pathol., 194: 15-19 (2001).
384. Sagone, A.L. et al.: Effect of catalase on the proliferation of human lymphocytes to phorbol myristate acetate. J. Immunol., 133: 1488-1494 (1984).
385. Sahasrabudhe, D.M. and Dusel, J.C.: Effect of murine interferon alpha/beta on tumor-induced suppressor function. Cancer. Immunol. Immunother., 39: 360-366 (1994).
386. Salazaronfray, F. et al.: IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J. Immunol., 154: 6291-6298 (1995).
387. Salazaronfray, F. et al.: Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J. Immunol., 159: 3195-3202 (1997).
388. Salmaggi, A. et al.: Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients. Cancer. Lett., 146: 169-172 (1999).
389. Salmon, M. et al.: The progressive differentiation of primed T cells is associated with an increasing susceptibility to apoptosis. Eur. J. Immunol., 24: 892-899 (1994).
390. Salvadori, S. et al.: Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors. J. Immunol., 153: 5176-5182 (1994).
391. Salvadori, S., Martinelli, G. and Zier, K.: Resection of solid tumors reverses T cell defects and restores protective immunity. J. Immunol., 164: 2214-2220 (2000).
392. Sanchez Rovira, P. et al.: Serum levels of intercellular adhesion molecule 1 (ICAM-1) in patients with colorectal cancer. Inhibitory effect on cytotoxicity. Eur. J. Cancer, 34: 394-398 (1998).
393. Sanda, M.G. et al.: Molecular characterization of defective antigen processing in human prostate cancer. J. Nat. Cancer. Inst., 87: 280-285 (1995).
394. Sander, B. and Boeryd, B.: Tumor necrosis factor-alpha expression in human primary malignant melanoma and its relationship to tumor infiltration by CD3(+) cells. Int. J. Cancer, 66: 42-47 (1996).
395. Santra, S. and Ghosh, S.K.: Interleukin-4 is effective in restoring cytotoxic T cell activity that declines during in vivo progression of a murine B lymphoma. Cancer. Immunol. Immunother., 44: 291-300 (1997).
396. Sarris,A.H. et al.: Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann. Oncol., 10: 433-440 (1999).
397. Scheibenbogen, C. et al.: Analysis of the T cell response to tumor and viral peptide antigens by an IFN gamma-elispot assay. Int. J. Cancer, 71: 932-936 (1997).
398. Schiott, A. et al.: Effects of transforming growth factor beta 1 expression in a rat colon carcinoma. Growth inhibition, leukocyte infiltration and production of interleukin-10 and tumor necrosis factor alpha. Cancer. Immunol. Immunother., 48: 579-587 (2000).
399. Schottelius, A.J.G. et al.: Interleukin-10 signaling blocks inhibitor of kappa B kinase activity and nuclear factor kappa B DNA binding. J. Biol. Chem., 274: 31868-31874 (1999).
400. Schreiber, H. et al.: Immunological enhancement of primary tumor development and its prevention. Semin. Cancer. Biol., 10: 351-357 (2000).
401. Schultze, J.L. et al.: Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood, 89: 3806-3816 (1997).
402. Seliger, B. et al.: Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Exp. Hematol., 25: 608-614 (1997a).
403. Seliger, B., Maeurer, M.J. and Ferrone, S.: TAP off. Tumours on. Immunol. Today, 18: 292-299 (1997b).
404. Seo, N. and Egawa, K.: Suppression of cytotoxic T lymphocyte activity by gamma/delta T cells in tumor-bearing mice. Cancer. Immunol. Immunother., 40: 358-366 (1995).
405. Seo, N. et al.: Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sezary syndrome. Its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity. Clin. Exp. Immunol., 112: 403-409 (1998).
406. Seo, N. et al.: Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J. Immunol., 163: 242-249 (1999).
407. Seung, L.P. et al.: Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc. Natl. Acad. Sci. USA, 92: 6254-6258 (1995a).
408. Seung, L.P., Seung, S.K. and Schreiber, H.: Antigenic cancer cells that escape immune destruction are stimulated by host cells. Cancer. Res., 55: 5094-5100 (1995b).
409. Seung, S., Urban, J.L. and Schreiber, H.: A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J. Exp. Med., 178: 933-940 (1993).
410. Shankaran, V. et al.: IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 410: 1107-1111 (2001).
411. Sharma, S. et al.: T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J. Immunol., 163: 5020-5028 (1999).
412. She, J. et al.: Generation of antigen- specific cytotoxic T lymphocytes and regulation of cytokine production takes place in the absence of CD3 zeta. Int. Immunol., 11: 845-858 (1999).
413. Shimizu, J., Yamazaki, S. and Sakaguchi, S.: Induction of tumor immunity by removing CD25(+)CD4(+) T cells. A common basis between tumor immunity and autoimmunity. J. Immunol., 163: 5211-5218 (1999).
414. Shimizu, M. et al.: Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma Neuro-2a cells. J. Immunol., 162: 7350-7357 (1999).
415. Shiraki, K. et al.: Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA, 94: 6420-6425 (1997).
416. Shrikant, P., Khoruts, A. and Mescher, M.F.: CTLA-4 blockade reverses CD8(+) T cell tolerance to tumor by a CD4(+) T cell- and IL-2-dependent mechanism. Immunity, 11: 483-493 (1999).
417. Siegel, C.T. et al.: Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J. Exp. Med., 191: 1945-1956 (2000).
418. Sjoberg, J. et al.: Interleukin-10 mRNA expression in B-cell chronic lymphocytic leukaemia inversely correlates with progression of disease. Br. J. Haematol., 92: 393-400 (1996).
419. Sloanlancaster, J., Evavold, B.D. and Allen, P.M.: Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature, 363: 156-159 (1993).
420. Smith, D.R. et al.: Production of interleukin-10 by human bronchogenic carcinoma. Am. J. Pathol., 145: 18-25 (1994).
421. Smyth, M.J. and Trapani, J.A.: Lymphocyte-mediated immunosurveillance of epithelial cancers? Trends Immunol., 22: 409-411 (2001).
422. Sotomayor, E.M. et al.: Conversion of tumor-specific CD4(+) T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nature. Med., 5: 780-787 (1999).
423. Speiser, D.E. et al.: In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J. Exp. Med., 190: 775-782 (1999).
424. Staveley O'Carroll, K. et al.: Induction of antigen-specific T cell anergy. An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA, 95: 1178-1183 (1998).
425. Steinbrink, K. et al.: Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood, 93: 1634-1642 (1999).
426. Stewart, T. et al.: Incidence of de novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet, 346: 796-798 (1995).
427. Stoeck, M. et al.: Stimulation of FACS-analysed CD4 and CD8 human tumour-infiltrating lymphocytes with ionomycin + phorbol-12, 13-dibutyrate does not overcome their proliferative deficit. Clin. Exp. Immunol., 79: 105-108 (1990).
428. Stolina, M. et al.: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol., 164: 361-370 (2000).
429. Straten, P.T. et al.: In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J. Immunol., 163: 443-447 (1999).
430. Stremmel, C. et al.: B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. J. Exp. Med., 189: 919-930 (1999).
431. Stutman, O.: Tumor development after 3-methylcholanthrene in immunologically-deficient nude mice. Science, 183: 534-536 (1970).
432. Suzue, K. et al.: Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc. Natl. Acad. Sci. USA, 94: 13146-13151 (1997).
433. Suzuki, I. and Fink, P.J.: Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J. Exp. Med., 187: 123-128 (1998).
434. Taga, K., Cherney, B. and Tosato, G.: IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int. Immunol., 5: 1599-1608 (1993).
435. Takao, S. et al.: Mucin core protein expression in extrahepatic bile duct carcinoma is associated with metastases to the liver and poor prognosis. Cancer, 86: 1966-1975 (1999).
436. Takenaga, K. et al.: Augmentation of in vivo growth of Lewis lung carcinoma cells transduced with granulocyte macrophage-colony stimulating factor gene. Cancer. Lett., 105: 33-37 (1996).
437. Tamada, K. et al.: Immunosuppressive activity of cloned natural killer [NK1.1(+)] T cells established from murine tumor-infiltrating lymphocytes. J. Immunol., 158: 4846-4854 (1997).
438. Tan, K.C. et al.: Epidermal cell presentation of tumorassociated antigens for induction of tolerance. J. Immunol., 153: 760-767 (1994).
439. Tartour, E. et al.: Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma. Relationship with TIL phenotype and function. Int. J. Cancer, 63: 205-212 (1995).
440. Terheyden, P. et al.: Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis. J. Invest. Dermatol., 112: 899-902 (1999).
441. Thomas, G.R. et al.: Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. Int. J. Cancer, 82: 377-384 (1999).
442. Thomas, W.D. et al.: Expression of the co-stimulatory molecule CD40 on melanoma cells. Int. J. Cancer, 68: 795-801 (1996).
443. Thurnher, M. et al.: Tumor-infiltrating T lymphocytes from renal-cell carcinoma express B7-1 (CD80): T-cell expansion by T-T cell co-stimulation. Int. J. Cancer, 62: 559-564 (1995).
444. Toes, R.E.M. et al.: Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol., 156: 3911-3918 (1996a).
445. Toes, R.E.M. et al.: Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA, 93: 7855-7860 (1996b).
446. Topalian, S.L., Kasid, A. and Rosenberg, S.A.: Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures. J. Immunol., 144: 4487-4495 (1990).
447. Torisu, H. et al.: Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma. Possible involvement of TNF alpha and IL-1 alpha. Int. J. Cancer, 85: 182-188 (2000).
448. Traversari, C. et al.: IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene. Therapy, 4: 1029-1035 (1997).
449. Tsuruma, T. et al.: Interleukin-10 reduces natural killer (NK) sensitivity of tumor cells by downregulating NK target structure expression. Cell. Immunol., 198: 103-110 (1999).
450. Tsushima, H. et al.: High levels of transforming growth factor beta 1 in patients with colorectal cancer. Association with disease progression. Gastroenterology, 110: 375-382 (1996).
451. Tsutsui, T. et al.: Administration of IL-12 induces a CD3(+)CD4(-)CD8(-)B220(+) lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells. J. Immunol., 159: 2599-2605 (1997).
452. Ugurel, S. et al.: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol., 19: 577-583 (2001).
453. Ungefroren, H. et al.: Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer. Res., 58: 1741-1749 (1998).
454. Uzzo, R.G. et al.: Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappa B activation in T cells. J. Clin. Invest., 104: 769-776 (1999).
455. Valmori, D. et al.: Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer. Res., 57: 735-741 (1997).
456. Vanbergen, C.A.M. et al.: Interleukin-10, interleukin-12, and tumor necrosis factor-alpha differentially influence the proliferation of human CD8(+) and CD4(+) T-cell clones. Ann. Hematol., 72: 245-252 (1996).
457. Vandenhove, L.E. et al.: Identification of an enriched CD4(+) CD8 alpha(++) CD8 beta(+) T-cell subset among tumor-infiltrating lymphocytes in human renal cell carcinoma. Int. J. Cancer, 71: 178-182 (1997).
458. Vanderhove, L.E. et al.: Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clin. Exp. Immunol., 109: 501-509 (1997).
459. Vanky, F. et al.: Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro. Cancer. Immunol. Immunother., 43: 317-323 (1997).
460. Varadhachary, A.S. et al.: Differential ability of T cell subsets to undergo activation-induced cell death. Proc. Natl. Acad. Sci. USA, 94: 5778-5783 (1997).
461. Venetsanakos, E. et al.: High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br. J. Cancer, 75: 1826-1830 (1997).
462. Vercelli, M. et al.: Relative survival in elderly cancer patients in Europe. Eur. J. Cancer, 34: 2264-2270 (1998).
463. Villunger, A. et al.: Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance. Blood, 90: 12-20 (1997).
464. Viret, C. et al.: T cell activation by antigens on human melanoma cells. Co-stimulation by B7-1 is neither sufficient nor necessary to stimulate IL-2 secretion by melanoma-specific T cell clones in vitro. Int. Immunol., 7: 1535-1543 (1995).
465. von Leoprechting, A. et al.: Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer. Res., 59: 1287-1294 (1999).
466. Vora, A.R. et al.: An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br. J. Cancer, 76: 836-844 (1997).
467. Vose, B.M. and Moore, M.: Suppressor cell activity of lymphocytes infiltrating human lung and breast tumours. Int. J. Cancer, 24: 579-585 (1979).
468. Wagner, S.N. et al.: Immune response against human primary malignant melanoma. A distinct cytokine mRNA profile associated with spontaneous regression. Lab. Invest., 78: 541-550 (1998).
469. Walker, P.R., Saas, P. and Dietrich, P.Y.: Role of Fas ligand (CD95L) in immune escape. The tumor cell strikes back. Commentary. J. Immunol., 158: 4521-4524 (1997).
470. Wang, Q. et al.: Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int. J. Cancer, 61: 780-785 (1995a).
471. Wang, Q. et al.: T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J. Immunol., 155: 1382-1392 (1995b).
472. Wang, R.F. and Taniguchi, M.: Limited T cell antigen receptor repertoire in tumor-infiltrating lymphocyte and inhibition of experimental lung metastasis of murine melanoma by anti-TCR antibody. J. Immunol., 154: 1797-1803 (1995).
473. Wang, Z.G. et al.: Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J. Exp. Med., 190: 205-215 (1999).
474. Warabi, M., Kitagawa, M. and Hirokawa, K.: Loss of MHC class II expression is associated with a decrease of tumor-infiltrating T cells and an increase of metastatic potential of colorectal cancer. Immunohistological and histopathological analyses as compared with normal colonic mucosa and adenomas. Pathol. Res. Pract., 196: 807-815 (2000).
475. Wei, W.Z. et al.: Elimination of V-beta-2 bearing T cells in BALB/c mice implanted with syngeneic preneoplastic and neoplastic mammary lesions. Cancer. Res., 51: 3331-3333 (1991).
476. Weidmann, E. et al.: Receptors for interleukin-2 on human squamous cell carcinoma cell lines and tumor in situ. Cancer. Res., 52: 5963-5970 (1992).
477. Weller, M. et al.: CD95-dependent T-cell killing by glioma cells expressing CD95 ligand. More on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain. Cell. Physiol. Biochem., 7: 282-288 (1997).
478. Wells, A.D. et al.: Restoration of MHC class I surface expression and endogenous antigen presentation by a molecular chaperone. Scand. J. Immunol., 45: 605-612 (1997).
479. Wen, T. et al.: CD28 is not required for rejection of unmanipulated syngeneic and autologous tumors. Eur. J. Immunol., 27: 1988-1993 (1997).
480. Wick, M. et al.: Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med., 186: 229-238 (1997).
481. Wiers, K. et al.: Failure of tumor-reactive lymph node cells to kill tumor in the presence of immunesuppressive CD34(+) cells can be overcome with vitamin D-3 treatment to diminish CD34(+) cell levels. Clin. Exp. Metastasis., 16: 275-282 (1998).
482. Wijesuriya, R. et al.: B cell-mediated down-regulation of IFN-gamma and IL-12 production induced during antitumor immune responses in the tumor-bearing state. Int. Immunol., 10: 1057-1065 (1998).
483. Willers, J. et al.: The interferon inhibiting cytokine IK is overexpressed in cutaneous T cell lymphoma derived tumor cells that fail to upregulate major histocompatibility complex class II upon interferon-gamma stimulation. J. Invest. Dermatol., 116: 874-879 (2001).
484. Wölfel, T. et al.: Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J. Exp. Med., 170: 797-810 (1989).
485. Wolpert, E.Z. et al.: Generation of CD8(+) T cells specific for transporter associated with antigen processing deficient cells. Proc. Natl. Acad. Sci. USA, 94: 11496-11501 (1997).
486. Wrann, M. et al.: T cell suppressor factor from human glioblastoma cells is a 12.5 kDa protein closely related to transforming growth factor-β. Embo. J., 6: 1633-1636 (1987).
487. Xu, Z.-Y. et al.: Overcoming suppression of antitumor immune reactivity in tumor-bearing rats by treatment with bleomycin. Cancer. Res., 48: 6658-6663 (1988).
488. Yamamoto, N. et al.: Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state. J. Immunol., 154: 2281-2290 (1995).
489. Yamamura, M. et al.: Local Expression of Antiinflammatory Cytokines in Cancer. J. Clin. Invest., 91: 1005-1010 (1993).
490. Yang, G.C. et al.: In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J. Immunol., 155: 3897-3903 (1995).
491. Yang, Y.F. et al.: Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade. The effect is manifested only at the restricted tumor-bearing stages. Cancer. Res., 57: 4036-4041 (1997).
492. Yashiro, Y. et al.: A fundamental difference in the capacity to induce proliferation of naive T cells between CD28 and other co- stimulatory molecules. Eur. J. Immunol., 28: 926-935 (1998).
493. Yasukawa, M. et al.: CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood, 92: 3355-3361 (1998).
494. Yasumura, S. et al.: Expression of interleukin 2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin 2. Int. J. Cancer, 59: 225-234 (1994).
495. Yoong, K.F. and Adams, D.H.: Interleukin 2 restores CD3-zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases. Br. J. Cancer, 77: 1072-1081 (1998).
496. Young, M.R.I. et al.: Mechanisms of immune suppression in patients with head and neck cancer. Influence on the immune infiltrate of the cancer. Int. J. Cancer, 67: 333-338 (1996).
497. Young, M.R.I. et al.: Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34(+) natural suppressor cells. Int. J. Cancer, 74: 69-74 (1997).
498. Young, M.R.I. et al.: Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34(+) progenitor cells. Hum. Immunol., 62: 332-341 (2001).
499. Yuan, A. et al.: Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Amer. J. Respir. Crit. Care. Med., 162: 1957-1963 (2000).
500. Yue, F.Y. et al.: Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class 1, HLA class II and ICAM-1 molecules. Int. J. Cancer, 71: 630-637 (1997).
501. Zaks, T.Z. et al.: Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor. Selective rescue by caspase inhibition. J. Immunol., 162: 3273-3279 (1999).
502. Zea, A.H. et al.: Alterations in T cell receptor and signal-transduction molecules in melanoma patients. Clinical Cancer Research, 1: 1327-1335 (1995).
503. Zea, A.H. et al.: Changes in signal transduction molecules in patients with lepromatous leprosy. Infect. Immun., (in press): (1997).
504. Zeidler, R. et al.: Downregulation of TAP-1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin 10. Blood, 90: 2390-2397 (1997).
505. Zeller, J.C. et al.: Induction of CD4(+) T cell allo-antigen-specific hyporesponsiveness by IL-10 and TGF-beta(1). J. Immunol., 163: 3684-3691 (1999).
506. Zhang, G.J. and Adachi, I.: Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer. Res., 19: 1427-1432 (1999).
507. Zheng, L.M. et al.: Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J. Exp. Med., 184: 579-584 (1996).
508. Zheng, P. et al.: Two mechanisms for tumor evasion of preexisting cytotoxic T cell responses. Lessons from recurrent tumors. Cancer. Res., 59: 3461-3467 (1999).